Molecular therapeutic approaches for pediatric acute myeloid leukemia

Frontiers in Oncology

Volumn 4 MAR, Issue , 2014, Pages

  Tasian, Sarah K ^a   Pollard, Jessica A ^b   Aplenc, Richard ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Acute myeloid leukemia; Clinical trial; Demethylating agents; Monoclonal antibodies; Pediatric; Precision medicine; Targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 2 (6 AMINO 9H PURIN 9 YL) 5 [[[3 [2 (5 TERT BUTYL 1H BENZIMIDAZOL 2 YL)ETHYL]CYCLOBUTYL](ISOPROPYL)AMINO]METHYL]TETRAHYDROFURAN 3,4 DIOL; 5 AZA 2' DEOXYCYTIDINE; ACTINIUM 225; ALISERTIB; AMG 330; AMG 900; AML02; ASP 2215; AZACITIDINE; BLINATUMOMAB; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CARFILZOMIB; CART 123; CART 33; CRENOLANIB; CSL 362; EVEROLIMUS; GEMTUZUMAB OZOGAMICIN; IGN523; IPILIMUMAB; JQ 1; LESTAURTINIB; LINIFANIB; LINTUZUMAB; MIDOSTAURIN; OXT 015; PANOBINOSTAT; PLX3397; QUIZARTINIB; RAPAMYCIN; SELINEXOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VORINOSTAT; [4 [2 (1H INDAZOL 3 YL)VINYL]PHENYL](1 PIPERAZINYL)METHANONE;

ACUTE GRANULOCYTIC LEUKEMIA; HUMAN; MOLECULAR BIOLOGY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW;

EID: 84901036213     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00055     Document Type: Review

References (143)

1. Meshinchi S, Arceci RJ. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist (2007) 12(3):341-55. doi:10.1634/theoncologist.12-3-341.
2. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol (2011) 29(5):551-65. doi:10.1200/JCO.2010.30.7405.
3. Moore AS, Kearns PR, Knapper S, Pearson AD, Zwaan CM. Novel therapies for children with acute myeloid leukaemia. Leukemia (2013) 27(7):1451-60. doi:10.1038/leu.2013.106.
4. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood (2012) 120(16):3187-205. doi:10.1182/blood-2012-03-362608.
5. Puumala SE, Ross JA, Aplenc R, Spector LG. Epidemiology of childhood acute myeloid leukemia. Pediatr Blood Cancer (2013) 60(5):728-33. doi:10.1002/pbc.24464.
6. Radhi M, Meshinchi S, Gamis A. Prognostic factors in pediatric acute myeloid leukemia. Curr Hematol Malig Rep (2010) 5(4):200-6. doi:10.1007/s11899-010-0060-z.
7. Juhl-Christensen C, Ommen HB, Aggerholm A, Lausen B, Kjeldsen E, Hasle H, et al. Genetic and epigenetic similarities and differences between childhood and adult AML. Pediatr Blood Cancer (2012) 58(4):525-31. doi:10.1002/pbc.23397.
8. Schuback HL, Arceci RJ, Meshinchi S. Somatic characterization of pediatric acute myeloid leukemia using next-generation sequencing. Semin Hematol (2013) 50(4):325-32. doi:10.1053/j.seminhematol.2013.09.003.
9. Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, et al. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood (2012) 119(16):3705-11. doi:10.1182/blood-2011-12-398370.
10. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem (2002) 13(1):47-58. doi:10.1021/bc010021y.
11. Walter RB, Gooley TA, van der Velden VH, Loken MR, van Dongen JJ, Flowers DA, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood (2007) 109(10):4168-70. doi:10.1182/blood-2006-09-047399.
12. Jilani I, Estey E, Huh Y, Joe Y, Manshouri T, Yared M, et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol (2002) 118(4):560-6. doi:10.1309/1WMW-CMXX-4WN4-T55U.
13. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 19(13):3244-54.
14. Larson RA, Sievers EL, Stadtmauer EA, Lowenberg B, Estey EH, Dombret H, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer (2005) 104(7):1442-52. doi:10.1002/cncr.21326.
15. Kell WJ, Burnett AK, Chopra R, Yin JA, Clark RE, Rohatiner A, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood (2003) 102(13):4277-83. doi:10.1182/blood-2003-05-1620.
16. Reinhardt D, Diekamp S, Fleischhack G, Corbacioglu C, Jurgens H, Dworzak M, et al. Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia. Onkologie (2004) 27(3):269-72. doi:10.1159/000075606.
17. Zwaan CM, Reinhardt D, Zimmerman M, Hasle H, Stary J, Stark B, et al. Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol (2010) 148(5):768-76. doi:10.1111/j.1365-2141.2009.08011.x.
18. Satwani P, Bhatia M, Garvin JH Jr, George D, Dela Cruz F, Le Gall J, et al. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen. Biol Blood Marrow Transplant (2012) 18(2):324-9. doi:10.1016/j.bbmt.2011.11.007.
19. Roman E, Cooney E, Harrison L, Militano O, Wolownik K, Hawks R, et al. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clin Cancer Res (2005) 11(19 Pt 2):7164s-70s. doi:10.1158/1078-0432.CCR-1004-0018.
20. Arceci RJ, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R, et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood (2005) 106(4):1183-8. doi:10.1182/blood-2004-10-3821.
21. Buckwalter M, Dowell JA, Korth-Bradley J, Gorovits B, Mayer PR. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Pharmacol (2004) 44(8):873-80. doi:10.1177/0091270004267595.
22. O'Hear C, Inaba H, Pounds S, Shi L, Dahl G, Bowman WP, et al. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer (2013) 119(22):4036-43. doi:10.1002/cncr.28334.
23. Aplenc R, Alonzo TA, Gerbing RB, Lange BJ, Hurwitz CA, Wells RJ, et al. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Clin Oncol (2008) 26(14):2390-3295. doi:10.1200/JCO.2007.13.0096.
24. Cooper TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer (2012) 118(3):761-9. doi:10.1002/cncr.26190.
25. Hasle H, Abrahamsson J, Forestier E, Ha SY, Heldrup J, Jahnukainen K, et al. Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood (2012) 120(5):978-84. doi:10.1182/blood-2012-03-416701.
26. Gamis A, Aplenc R, Alonzo TA, Sung L, Meshinchi S, Gerbing RB, et al. Gemtuzumab ozogamicin (GO) in children with de novo acute myeloid leukemia (AML) improves event-free survival (EFS) by reducing relapse risk-results from the randomized Phase III Children's Oncology Group (COG) trial, AAML0531. Blood (2013) 122(21):355.
27. Pollard JA, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch B, Aplenc R, et al. Negative prognostic impact of high CD33 expression is negated with the use of gemtuzumab ozogamicin: a report from the Children's Oncology Group. Blood (2013) 122(21):491.
28. Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood (2013) 121(24):4854-60. doi:10.1182/blood-2013-01-466706.
29. Ravandi F, Estey EH, Appelbaum FR, Lo-Coco F, Schiffer CA, Larson RA, et al. Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol (2012) 30(32):3921-3. doi:10.1200/JCO.2012.43.0132.
30. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol (2011) 29(4):369-77. doi:10.1200/JCO.2010.31.4310.
31. Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol (2012) 30(32):3924-31. doi:10.1200/JCO.2012.42.2964.
32. Burnett AK, Hills RK, Hunter AE, Milligan D, Kell WJ, Wheatley K, et al. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia (2013) 27(1):75-81. doi:10.1038/leu.2012.229.
33. Health USNIo. Clinical Trials. (2013) [cited 2014 Jan 21]. Available from: www.clinicaltrials.gov.
34. Cowan AJ, Laszlo GS, Estey EH, Walter RB. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Front Biosci (2013) 18:1311-34. doi:10.2741/4181.
35. Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood (2013) 122(8):1455-63. doi:10.1182/blood-2013-03-491506.
36. Topp MS, Gokbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood (2012) 120(26):5185-7. doi:10.1182/blood-2012-07-441030.
37. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol (2011) 29(18):2493-8. doi:10.1200/JCO.2010.32.7270.
38. Krupka C, Kufer P, Kischel R, Zugmaier G, Bogeholz J, Kohnke T, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood (2014) 123(3):356-65. doi:10.1182/blood-2013-08-523548.
39. Laszlo GS, Gudgeon CJ, Harrington KH, Dell'Aringa J, Newhall KJ, Means GD, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood (2014) 123(4):554-61. doi:10.1182/blood-2013-09-527044.
40. Aigner M, Feulner J, Schaffer S, Kischel R, Kufer P, Schneider K, et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia (2013) 27(5):1107-15. doi:10.1038/leu.2012.341.
41. Jurcic JG. What happened to anti-CD33 therapy for acute myeloid leukemia? Curr Hematol Malig Rep (2012) 7(1):65-73. doi:10.1007/s11899-011-0103-0.
42. Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood (2006) 108(12):3654-61. doi:10.1182/blood-2006-03-009233.
43. Pollard JA, Alonzo TA, Gerbing RB, Woods WG, Lange BJ, Sweetser DA, et al. FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia. Blood (2006) 108(8):2764-9. doi:10.1182/blood-2006-04-012260.
44. Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S, et al. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol (2013) 161(5):659-66. doi:10.1111/bjh.12299.
45. Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients. Blood (2008) 111(5):2527-37. doi:10.1182/blood-2007-05-091215.
46. Sallmyr A, Fan J, Datta K, Kim KT, Grosu D, Shapiro P, et al. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood (2008) 111(6):3173-82. doi:10.1182/blood-2007-05-092510.
47. Gu TL, Nardone J, Wang Y, Loriaux M, Villen J, Beausoleil S, et al. Survey of activated FLT3 signaling in leukemia. PLoS One (2011) 6(4):e19169. doi:10.1371/journal.pone.0019169.
48. Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, Levis M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood (2010) 115(7):1425-32. doi:10.1182/blood-2009-09-242859.
49. Wiernik PH. FLT3 inhibitors for the treatment of acute myeloid leukemia. Clin Adv Hematol Oncol (2010) 8(6):429-36.
50. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst (2008) 100(3):184-98. doi:10.1093/jnci/djm328.
51. Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood (2011) 117(12):3294-301. doi:10.1182/blood-2010-08-301796.
52. Knapper S, Burnett AK, Littlewood T, Kell WJ, Agrawal S, Chopra R, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood (2006) 108(10):3262-70. doi:10.1182/blood-2006-04-015560.
53. Hu S, Niu H, Inaba H, Orwick S, Rose C, Panetta JC, et al. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J Natl Cancer Inst (2011) 103(11):893-905. doi:10.1093/jnci/djr107.
54. Levis M, Small D. Small molecule FLT3 tyrosine kinase inhibitors. Curr Pharm Des (2004) 10(11):1183-93. doi:10.2174/1381612043452604.
55. Swords R, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia (2012) 26(10):2176-85. doi:10.1038/leu.2012.114.
56. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood (2009) 114(14):2984-92. doi:10.1182/blood-2009-05-222034.
57. Pratz KW, Cortes J, Roboz GJ, Rao N, Arowojolu O, Stine A, et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood (2009) 113(17):3938-46. doi:10.1182/blood-2008-09-177030.
58. Burton E, Wong B, Zhang J, West B, Bollag G, Habets G, et al. The novel inhibitor PLX3397 effectively inhibits FLT3-mutant AML. Blood (2011) 118(21):3632.
59. Wang ES, Yee K, Koh LP, Hogge D, Enschede S, Carlson DM, et al. Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia. Leuk Lymphoma (2012) 53(8):1543-51. doi:10.3109/10428194.2012.660631.
60. Chu SH, Small D. Mechanisms of resistance to FLT3 inhibitors. Drug Resist Updat (2009) 12(1-2):8-16. doi:10.1016/j.drup.2008.12.001.
61. Weisberg E, Sattler M, Ray A, Griffin JD. Drug resistance in mutant FLT3-positive AML. Oncogene (2010) 29(37):5120-34. doi:10.1038/onc.2010.273.
62. Williams AB, Nguyen B, Li L, Brown P, Levis M, Leahy D, et al. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia (2013) 27(1):48-55. doi:10.1038/leu.2012.191.
63. Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, et al. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood (2013) 122(22):3607-15. doi:10.1182/blood-2013-07-513044.
64. Galanis A, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J, et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood (2014) 123(1):94-100. doi:10.1182/blood-2013-10-529313.
65. Heinrich MC, Griffith D, McKinley A, Patterson J, Presnell A, Ramachandran A, et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res (2012) 18(16):4375-84. doi:10.1158/1078-0432.CCR-12-0625.
66. Langdon WY. FLT3 signaling and the development of inhibitors that target FLT3 kinase activity. Crit Rev Oncog (2012) 17(2):199-209. doi:10.1615/CritRevOncog.v17.i2.50.
67. Grunwald MR, Levis MJ. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int J Hematol (2013) 97(6):683-94. doi:10.1007/s12185-013-1334-8.
68. Altman JK, Foran JM, Pratz KW, Trone D, Gammon G, Cortes JE, et al. Results of a Phase 1 study of quizartinib (AC220, ASP2689) in combination with induction and consolidation chemotherapy in younger patients with newly diagnosed acute myeloid leukemia. Blood (2013) 122(21):623.
69. Burnett AK, Bowen D, Russell N, Knapper S, Milligan D, Hunter AE, et al. AC220 (Quizartinib) can be safely combined with conventional chemotherapy in older patients with newly diagnosed acute myeloid leukaemia: experience from the AML18 pilot trial. Blood (2013) 122(21)622.
70. Brown P, Meshinchi S, Levis M, Alonzo TA, Gerbing R, Lange B, et al. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Blood (2004) 104(6):1841-9. doi:10.1182/blood-2004-03-1034.
71. Brown P, Levis M, Shurtleff S, Campana D, Downing J, Small D. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood (2005) 105(2):812-20. doi:10.1182/blood-2004-06-2498.
72. Brown P, Levis M, McIntyre E, Griesemer M, Small D. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner. Leukemia (2006) 20(8):1368-76. doi:10.1038/sj.leu.2404277.
73. Brown P. Treatment of infant leukemias: challenge and promise. Hematology Am Soc Hematol Educ Program (2013) 2013:596-600. doi:10.1182/asheducation-2013.1.596.
74. Widemann BC, Kim A, Fox E, Baruchel S, Adamson PC, Ingle AM, et al. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin Cancer Res (2012) 18(21):6011-22. doi:10.1158/1078-0432.CCR-11-3284.
75. Watt TC, Cooper T. Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia. Pediatr Blood Cancer (2012) 59(4):756-7. doi:10.1002/pbc.23394.
76. Inaba H, Rubnitz JE, Coustan-Smith E, Li L, Furmanski BD, Mascara GP, et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol (2011) 29(24):3293-300. doi:10.1200/JCO.2011.34.7427.
77. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol (2010) 28(11):1856-62. doi:10.1200/JCO.2009.25.4888.
78. Serve H, Krug U, Wagner R, Sauerland MC, Heinecke A, Brunnberg U, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol (2013) 31(25):3110-8. doi:10.1200/JCO.2012.46.4990.
79. Pollard JA, Chang BH, Cooper TM, Gross T, Gupta S, Ho PA, et al. Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD+ AML. Blood (2013) 122(21):3969.
80. Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood (2010) 115(12):2372-9. doi:10.1182/blood-2009-09-241075.
81. Levis MJ, Perl AE, Dombret H, Dohner H, Steffen B, Rousselot P, et al. Final results of a Phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation. Blood (2012) 120(21):673.
82. Cooper TM, Malvar J, Cassar J, Eckroth E, Sposto R, Gaynon P, et al. A Phase I study of AC220 (Quizartinib) in combination with cytarabine and etoposide in relapsed/refractory childhood ALL and AML: a therapeutic advances in childhood leukemia & lymphoma (TACL) study. Blood (2013) 122(21):624.
83. Dai J, Kong Y, Si L, Chi Z, Cui C, Sheng X, et al. Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib. Clin Cancer Res (2013) 19(24):6935-42. doi:10.1158/1078-0432.CCR-13-1266.
84. Smith CC, Shah NP. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. Am Soc Clin Oncol Educ Book (2013) 33:313-8. doi:10.1200/EdBook_AM.2013.33.313.
85. Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, et al. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica (2010) 95(5):819-28. doi:10.3324/haematol.2009.013797.
86. Perl AE, Kasner MT, Shank D, Luger SM, Carroll M. Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. Clin Cancer Res (2012) 18(6):1716-25. doi:10.1158/1078-0432.CCR-11-2346.
87. Martelli AM, Evangelisti C, Chappell W, Abrams SL, Basecke J, Stivala F, et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia (2011) 25(7):1064-79. doi:10.1038/leu.2011.46.
88. Janes MR, Fruman DA. The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia. Methods Mol Biol (2012) 821:251-65. doi:10.1007/978-1-61779-430-8_15.
89. Vu C, Fruman DA. Target of rapamycin signaling in leukemia and lymphoma. Clin Cancer Res (2010) 16(22):5374-80. doi:10.1158/1078-0432.CCR-10-0480.
90. Jeong JY, Kim KS, Moon JS, Song JA, Choi SH, Kim KI, et al. Targeted inhibition of phosphatidyl inositol-3-kinase p110beta, but not p110alpha, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers. Apoptosis (2013) 18(4):509-20. doi:10.1007/s10495-013-0807-9.
91. Moore AS, Blagg J, Linardopoulos S, Pearson AD. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia (2010) 24(4):671-8. doi:10.1038/leu.2010.15.
92. Hartsink-Segers SA, Zwaan CM, Exalto C, Luijendijk MW, Calvert VS, Petricoin EF, et al. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target. Leukemia (2013) 27(3):560-8. doi:10.1038/leu.2012.256.
93. Wen Q, Goldenson B, Silver SJ, Schenone M, Dancik V, Huang Z, et al. Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell (2012) 150(3):575-89. doi:10.1016/j.cell.2012.06.032.
94. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood (2001) 98(8):2301-7. doi:10.1182/blood.V98.8.2301.
95. Stapnes C, Doskeland AP, Hatfield K, Ersvaer E, Ryningen A, Lorens JB, et al. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol (2007) 136(6):814-28. doi:10.1111/j.1365-2141.2007.06504.x.
96. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood (2005) 105(8):3058-65. doi:10.1182/blood-2004-07-2911.
97. Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol (2013) 31(7):923-9. doi:10.1200/JCO.2012.45.2177.
98. Blum W, Schwind S, Tarighat SS, Geyer S, Eisfeld AK, Whitman S, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood (2012) 119(25):6025-31. doi:10.1182/blood-2012-03-413898.
99. Muscal JA, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern RM, et al. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). Pediatr Blood Cancer (2013) 60(3):390-5. doi:10.1002/pbc.24271.
100. Messinger YH, Gaynon PS, Sposto R, van der Giessen J, Eckroth E, Malvar J, et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Blood (2012) 120(2):285-90. doi:10.1182/blood-2012-04-418640.
101. Messinger Y, Gaynon P, Raetz E, Hutchinson R, Dubois S, Glade-Bender J, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer (2010) 55(2):254-9. doi:10.1002/pbc.22456.
102. Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, Adamson PC, et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res (2007) 13(5):1516-22. doi:10.1158/1078-0432.CCR-06-2173.
103. Horton TM, Lu X, O'Brien MM, Borowitz MJ, Devidas M, Raetz EA, et al. Bortezomib reinduction therapy to improve response rates in pediatric ALL in first relapse: a Children's Oncology Group (COG) study (AALL07P1). J Clin Oncol (2013) 31(Suppl):10003.
104. Horton TM, Perentesis J, Gamis AS, Alonzo TA, Gerbing RB, Ballard J, et al. A Phase 2 study of bortezomib combined with reinduction chemotherapy in children and young adults with recurrent, refractory or secondary acute myeloid leukemia: a Children's Oncology Group (COG) Study. Blood (2012) 120(21):3580.
105. Damm F, Thol F, Hollink I, Zimmermann M, Reinhardt K, van den Heuvel-Eibrink MM, et al. Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. Leukemia (2011) 25(11):1704-10. doi:10.1038/leu.2011.142.
106. Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, et al. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia (2010) 24(5):909-13. doi:10.1038/leu.2010.56.
107. Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, et al. Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG. Blood (2011) 118(17):4561-6. doi:10.1182/blood-2011-04-348888.
108. Liang DC, Liu HC, Yang CP, Jaing TH, Hung IJ, Yeh TC, et al. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A. Blood (2013) 121(15):2988-95. doi:10.1182/blood-2012-06-436782.
109. Thol F, Heuser M, Damm F, Klusmann JH, Reinhardt K, Reinhardt D. DNMT3A mutations are rare in childhood acute myeloid leukemia. Haematologica (2011) 96(8):1238-40. doi:10.3324/haematol.2011.046839.
110. Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic RB, Bloomfield CD, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia (2012) 26(5):1106-7. doi:10.1038/leu.2011.342.
111. Phillips CL, Davies SM, McMasters R, Absalon M, O'Brien M, Mo J, et al. Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults. Br J Haematol (2013) 161(3):406-10. doi:10.1111/bjh.12268.
112. Gore L, Macy ME, Mechinaud F, Narendran A, Alvaro F, Arndt CAS, et al. Interim report of a randomized, open-label, multicenter study to evaluate the safety and efficacy of decitabine as an epigenetic priming agent when combined with induction chemotherapy in pediatric patients (pts) with newly diagnosed acute myelogenous leukemia (AML). Blood (2012) 120(21):1517.
113. Kuhn MWM, Hadler M, Daigle SR, Chen C-W, Sinha AU, Krivtsov AV, et al. Myeloid leukemia cells with MLL partial tandem duplication are sensitive to pharmacological inhibition of the H3K79 methyltransferase DOT1L. Blood (2012) 120(21):1256.
114. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 20(1):66-78. doi:10.1016/j.ccr.2011.06.010.
115. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 20(1):53-65. doi:10.1016/j.ccr.2011.06.009.
116. Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, Macbeth KJ, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol (2011) 29(18):2521-7. doi:10.1200/JCO.2010.34.4226.
117. Garcia-Manero G, Stoltz ML, Ward MR, Kantarjian H, Sharma S. A pilot pharmacokinetic study of oral azacitidine. Leukemia (2008) 22(9):1680-4. doi:10.1038/leu.2008.145.
118. Stathis A, Hotte SJ, Chen EX, Hirte HW, Oza AM, Moretto P, et al. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clin Cancer Res (2011) 17(6):1582-90. doi:10.1158/1078-0432.CCR-10-1893.
119. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res (2006) 66(12):6361-9. doi:10.1158/0008-5472.CAN-06-0080.
120. Walter RB, Medeiros BC, Gardner KM, Orlowski KF, Gallegos L, Scott BL, et al. Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study. Haematologica (2014) 99(1):54-9. doi:10.3324/haematol.2013.096545.
121. Tan P, Wei A, Mithraprabhu S, Cummings N, Liu HB, Perugini M, et al. Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer J (2014) 4:e170. doi:10.1038/bcj.2013.68.
122. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A (2011) 108(40):16669-74. doi:10.1073/pnas.1108190108.
123. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 478(7370):524-8. doi:10.1038/nature10334.
124. Herrmann H, Blatt K, Shi J, Gleixner KV, Cerny-Reiterer S, Mullauer L, et al. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor-cells in acute myeloid leukemia AML. Oncotarget (2012) 3(12):1588-99.
125. Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myeloid leukemia (AML) cells. Mol Cancer Ther (2014). doi:10.1158/1535-7163.MCT-13-0770.
126. Rodriguez M, Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, et al. Combined therapy with BRD4 antagonist and FLT3 inhibitor exerts synergistic activity against cultured and primary AML blast progenitors expressing FLT-ITD. Blood (2013) 122(21):3821.
127. Braun T, Coude MM, Berrou J, Bertrand S, Riveiro E, Heralt P, et al. Preclinical study of the bromodomain inhibitor OTX015 in acute myeloid (AML) and lymphoid (ALL) leukemias. Blood (2013) 122(21):4218.
128. Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol (2013) 161(1):117-27. doi:10.1111/bjh.12231.
129. Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood (2012) 120(23):4621-34. doi:10.1182/blood-2012-05-429506.
130. Etchin J, Sun Q, Kentsis A, Farmer A, Zhang ZC, Sanda T, et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia (2013) 27(1):66-74. doi:10.1038/leu.2012.219.
131. Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med (2014) 65:333-47. doi:10.1146/annurev-med-060512-150254.
132. Shah NN, Dave H, Wayne AS. Immunotherapy for pediatric leukemia. Front Oncol (2013) 3:166. doi:10.3389/fonc.2013.00166.
133. Lee DW, Barrett DM, Mackall C, Orentas R, Grupp SA. The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res (2012) 18(10):2780-90. doi:10.1158/1078-0432.CCR-11-1920.
134. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 368(16):1509-18. doi:10.1056/NEJMoa1215134.
135. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 5(177):177ra38. doi:10.1126/scitranslmed.3005930.
136. Peinert S, Prince HM, Guru PM, Kershaw MH, Smyth MJ, Trapani JA, et al. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther (2010) 17(5):678-86. doi:10.1038/gt.2010.21.
137. Tettamanti S, Marin V, Pizzitola I, Magnani CF, Giordano Attianese GM, Cribioli E, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol (2013) 161(3):389-401. doi:10.1111/bjh.12282.
138. Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood (2013) 122(18):3138-48. doi:10.1182/blood-2012-12-474056.
139. Marin V, Pizzitola I, Agostoni V, Attianese GM, Finney H, Lawson A, et al. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica (2010) 95(12):2144-52. doi:10.3324/haematol.2010.026310.
140. Dutour A, Marin V, Pizzitola I, Valsesia-Wittmann S, Lee D, Yvon E, et al. In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia. Adv Hematol (2012) 2012:683065. doi:10.1155/2012/683065.
141. Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, et al. Efficacy against human acute myeloid leukemia and myeloablation of normal hematopoiesis in a mouse model using chimeric antigen receptor-modified T cells. Blood (2014). doi:10.1182/blood-2013-09-529537.
142. Downing JR, Wilson RK, Zhang J, Mardis ER, Pui CH, Ding L, et al. The pediatric cancer genome project. Nat Genet (2012) 44(6):619-22. doi:10.1038/ng.2287.
143. Meshinchi S, Ries RE, Trevino LR, Hampton OA, Alonzo TA, Farrar JE, et al. Identification of novel somatic mutations, regions of recurrent loss of heterozygosity (LOH) and significant clonal evolution from diagnosis to relapse in childhood AML determined by exome capture sequencing-an NCI/COG target AML study. Blood (2012) 120(21):123.